ACAD9

Across TCGA pan-cancer cohorts, ACAD9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACAD9 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACAD9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACAD9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where ACAD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.834	0.610	.009	15	view →
LUAD	DFS	Median	II,III,IV	0.692	0.318	<.001	8	view →
CCRCC	DFS	Tertile	All	0.683	0.896	.024	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
UCEC	OS	Median	All	0.855	0.971	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACAD9–HNSC (OS)

Open the HNSC breakdown →